Stock comparison
Neurocrine Biosciences
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
NBIX
Neurocrine Biosciences
Market cap
$15.14B
Sector
Healthcare
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | NBIX | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 64C | RMD |
| Benjamin Graham | 68B | 67B | NBIX |
| Philip Fisher | 70B | 67B | NBIX |
| Peter Lynch | 55C | 50C | NBIX |
| Joel Greenblatt | 45D | 39D | NBIX |
| Charlie Munger | 50C | 61C | RMD |
| Terry Smith | 53C | 65B | RMD |
Side-by-side metrics
| Metric | NBIX | RMD |
|---|---|---|
| Market cap | $15.14B | $29.57B |
| P/E (TTM) | 22.6x | 19.6x |
| EV/EBIT | 24.7x | 17.1x |
| ROIC (TTM) | 13.68% | 19.63% |
| Gross margin | 98.17% | 61.69% |
| Net margin | 21.55% | 27.44% |
| Revenue CAGR 5y | 26.04% | 12.64% |
| EPS CAGR 5y | 50.0% | 30.73% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
NBIX leads on
- Revenue CAGR 5y26.04%vs 12.64%+51%
- EPS CAGR 5y50.0%vs 30.73%+39%
- Gross margin98.17%vs 61.69%+37%
- Debt / Equity0.1xvs 0.1x+8%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$29.57Bvs $15.14B+49%
- EV/EBIT17.1xvs 24.7x+31%
- ROIC (TTM)19.63%vs 13.68%+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.